Nanjing Pharmaceutical Group Co., Ltd. (600713.SH) Latest Company News

Sep 7, 2026, 09:13 UTC
Nanjing Pharmaceutical's non-independent director Zuo Xiangyuan resigned due to work changes, and the controlling shareholder nominated Huang Cheng as a candidate for the 10th board of directors.
Source:
- finance.sina.cn
Aug 28, 2026, 08:24 UTC
Nanjing Pharmaceutical announced plans to issue ultra-short-term financing bonds to institutional investors in the China interbank bond market, subject to shareholder approval and registration with the National Association of Financial Market Institutional Investors.
Source:
- finance.sina.cn
- finance.sina.cn
Aug 28, 2026, 08:24 UTC
Nanjing Pharmaceutical announced postponement of its digital transformation project completion date from August 2026 to December 2027.
Source:
- finance.sina.cn
Aug 28, 2026, 08:23 UTC
Nanjing Pharmaceutical Co., Ltd. announced a cash dividend of 0.9 yuan per 10 shares (tax included), with total distribution of 118 million yuan based on total share capital of 1.308 billion shares.
Source:
- finance.sina.cn
- finance.sina.cn
Aug 28, 2026, 08:23 UTC
Nanjing Pharmaceutical Co., Ltd. announced its first-half 2026 results: revenue of 27.823 billion yuan, down 0.52% year-on-year; net profit attributable to shareholders of 294 million yuan, up 1.10% year-on-year.
Source:
- finance.sina.cn
- finance.sina.cn
Jul 7, 2026, 08:28 UTC
Nanjing Pharmaceutical's controlled subsidiary Qianglian No.1 Fund is acquiring 44.95% of Daqing Bio and 50.98% of Kejian Technology, with the Kejian Technology seller changed from Du Zhanjun and Li Cihui to Du Mengyu.
Source:
- finance.sina.cn
Jul 2, 2026, 04:56 UTC
Nanjing Pharmaceutical and others established a scientific instrument company, Nanjing Pharmaceutical (Hubei) Scientific Instrument Co., Ltd., with a registered capital of 10 million yuan.
Source:
- finance.sina.cn

600713.SH

Nanjing Pharmaceutical's non-independent director Zuo Xiangyuan resigned due to work changes, and the controlling shareholder nominated Huang Cheng as a candidate for the 10th board of directors.

Nanjing Pharmaceutical announced plans to issue ultra-short-term financing bonds to institutional investors in the China interbank bond market, subject to shareholder approval and registration with the National Association of Financial Market Institutional Investors.

Nanjing Pharmaceutical announced postponement of its digital transformation project completion date from August 2026 to December 2027.

Nanjing Pharmaceutical Co., Ltd. announced a cash dividend of 0.9 yuan per 10 shares (tax included), with total distribution of 118 million yuan based on total share capital of 1.308 billion shares.

Nanjing Pharmaceutical Co., Ltd. announced its first-half 2026 results: revenue of 27.823 billion yuan, down 0.52% year-on-year; net profit attributable to shareholders of 294 million yuan, up 1.10% year-on-year.

Nanjing Pharmaceutical's controlled subsidiary Qianglian No.1 Fund is acquiring 44.95% of Daqing Bio and 50.98% of Kejian Technology, with the Kejian Technology seller changed from Du Zhanjun and Li Cihui to Du Mengyu.

Nanjing Pharmaceutical and others established a scientific instrument company, Nanjing Pharmaceutical (Hubei) Scientific Instrument Co., Ltd., with a registered capital of 10 million yuan.